Molecular and epidemiology studies of HIV-1 prevalence in the Republic of Sakha (Yakutia)

Voprosy Virusologii

Volumn 56, Issue 5, 2011, Pages 30-34

  Kazennova, E V ^a   Antonova, O V ^a   Kuzin, S N ^c   Serkina, T P ^b   Sokolova, L S ^b   Vasilyev, A V ^a   Lapovok, I A ^a   Bobkova, M R ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b Yakutsk Republican Center for AIDS Prevention and Control   (Russian Federation)

^c MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

Drug resistance mutations; HIV 1 variants; Human immunodeficiency virus type I (HIV 1)

Indexed keywords

EID: 82455174398     PISSN: 05074088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bobkov A., Cheingsong-Popov R., Selimova L. et al. An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain // AIDS Res. Hum. Retrovirus. - 1997. - Vol. 13. - P. 1195-1201.
2. Bobkov A., Kazennova E., Selimova L. et al. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: Identification of subtype A, subtype B, and novel gagA/envB recombinants//AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14. - P. 669-676.
3. Bobkov A. F., Lukashov V. V, Goudsmit J., Weber J. N. Silent mutation in the V3 region characteristic of HIV type 1 env subtype B strains from Injecting Drug Users in the Former Soviet Union // AIDS Res. Hum. Retrovirus. - 2000. - Vol. 16. - P. 291-294.
4. Bobkova M. R., Kazennova E. V., Selimova L. M. et al. Serological approaches to subtyping of HIV-1 in injecting drug users in Russia: evidence of subtype homogeneity at the main sites of the epidemic // Int. J. STD AIDS. - 2001. - Vol. 12. - P. 34-40.
5. Delwart E., Shpaer E. G., Louwagie J. et al. Genetic relationships determined by a DNA heteroduplex mobility assay analysis of HIV-1 env genes // Science. - 1993. - Vol. 262. - P. 1257-1261.
6. Dorr P., Westby M., Dobbs S. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity // Antimicrob. Agents Chemother. - 2005. - Vol. 49. - P. 4721-4732.
7. Heyndrickx L., Janssens W., Zekeng L. et al. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay // J. Virol. - 2000. - Vol. 74. - P. 363-370.
8. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequencer // J. Mol. Evol. - 1980. - Vol. 16. - P. 111-120.
9. Lukashov V. V., Karamov E. V., Eremin V. F. et al. Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus // AIDS Res. Hum. Retrovirus. - 1998. - Vol. 14. - P. 1299-1303.
10. Salzwedel K, Martin D. E., Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure // AIDS Rev. - 2007. - Vol. 9. - P. 162-172.
11. Yebra G., Holguin A. The maturation inhibitor bevirimat (PA457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants // Antivir. Ther. - 2008. - Vol. 13. - P. 1083-1085.